Navigation Links
NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD & NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS
Date:6/1/2009 

    - Results from a randomized Phase IIb trial reported at 2009 ASCO Annual
    Meeting -

MISSISSAUGA, ON, June 1 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex: YMI, TSX:YM, AIM:YMBA), a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development, today reported that results from a randomized trial of nimotuzumab (aka BIOMAb/TheraCIM/h-R3) in patients with inoperable, locoregionally advanced Stage III/IVa head and neck cancer conducted by Reddy BK et al (Kidwai Memorial Institute of Oncology, Bangalore, India), were presented in a poster at the 2009 ASCO Annual Meeting. The trial demonstrates that the efficacy of nimotuzumab compares favorably to results reported for cetuximab, an EGFR-targeting antibody marketed as Erbitux(R), but that this efficacy was not accompanied by the severe toxicities reported in patients treated with cetuximab. The authors further conclude that this trial is the first randomized study in head and neck cancer to their knowledge that challenges the adopted tenet that the efficacy of EGFR inhibitors is linked to the toxicity of the class.

"These data are further evidence of the unsupported extrapolation to the class of the toxicity/benefit correlation in the marketed EGFR drugs. The trial data demonstrate that patients have the prospect of equivalent clinical benefit from nimotuzumab as from the rest of the class without the physical, emotional and financial costs that result from the numerous and severe toxicities of Erbitux(R) which are a consequence of the demonstrable inability of that drug to discriminate between healthy cells and tumor cells," said David Allan, Chairman and CEO of YM BioSciences. "We expect that, as the numerous randomized trials currently ongoing worldwide with nimotuzumab re
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
2. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
3. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
4. YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION
5. YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB COLORECTAL CANCER TRIAL FIRST COHORT IS CLOSED TO ACCRUAL
6. YM BIOSCIENCES REPORTS NIMOTUZUMAB NSCLC CLINICAL DATA AT ASCO ANNUAL MEETING
7. NIMOTUZUMAB CLINICAL DATA PRESENTED AT ASCO ANNUAL MEETING
8. NOTICE OF YM BIOSCIENCES CONFERENCE CALL TO DISCUSS PHASE II DATA FOR NIMOTUZUMAB IN METASTATIC COLORECTAL CANCER
9. YM BIOSCIENCES NIMOTUZUMAB SELECTED FOR MULTINATIONAL PHASE III TRIAL BY NATIONAL CANCER CENTRE OF SINGAPORE
10. YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER
11. YM BIOSCIENCES ANNOUNCES RESULTS OF RANDOMIZED NIMOTUZUMAB STUDY TO BE PRESENTED IN A POSTER AT ASCO ANNUAL MEETING
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2012)... physicist, vanadium oxide (VO2) may be the coolest material you,ve ... a window coating and an optical switch. And thanks to ... a new way to reversibly alter VO2,s electronic properties by ... , So what is VO2? It,s an oxidized form of ... reacts with vanadium to form VO2, the atoms form crystals ...
(Date:5/21/2012)... May 21, 2012   Cord Blood America, Inc ... CBAI ), the umbilical cord blood stem cell ... potential of stem cells to families nationwide and internationally, ... 2012 increased by 6.7%  to $1.55 million compared to ... announced a gross profit of $1.12 million in the ...
(Date:5/21/2012)... The Houston Technology Center (HTC), Texas, ... annual gala, "A Celebration of Entrepreneurs . ... made a significant impact on the region,s economy; ... The Houston Technology Center named Beth Williams, CEO ... the Founder and CEO of TechTrans International, Inc., ...
(Date:5/21/2012)... May 21, 2012  Neuralstem, Inc. (NYSE MKT: ... will present at the World Stem Cells & ... on Tuesday, May 22nd at 12:30 PM. Mr. ... will review Neuralstem,s cellular therapy trial in ALS, ... disorder (MDD), and provide an overview on plans ...
Breaking Biology Technology:Reversible doping: Hydrogen flips switch on vanadium oxide 2Reversible doping: Hydrogen flips switch on vanadium oxide 3Cord Blood America Announces First Quarter Financial Results 2Cord Blood America Announces First Quarter Financial Results 3Leading Technology Incubator Honors Extraordinary Entrepreneurs 2Leading Technology Incubator Honors Extraordinary Entrepreneurs 3Neuralstem CEO to Present at the World Stem Cells and Regenerative Medicine Congress in London 2
... Mich., May 9 Dr. Michael W. Long ... Innovator of the Year.,The "Leader & Innovator" award ... of Michigan who have demonstrated or created unique,ideas, ... of life in our,communities. Nominees were recognized this ...
... 9 ,EUSA Pharma Inc (,EUSA,), a transatlantic specialty ... care, today announced that,it has completed its acquisition ... at a special meeting on 8 May., ... shareholders will,receive $0.62 per share, valuing the company ...
... ,Takeda Pharmaceutical Company Limited, "Takeda", (TSE: 4502) and ... announced the,successful completion of Takeda,s cash tender offer ... all outstanding shares,of Millennium common stock for US$25.00 ... the tender offer expired at 12:00,midnight, New York ...
Other Biology Technology:President and CEO of Velcura Therapeutics Inc. Named the 2008 Grant Thornton Leader and Innovator of the Year 2President and CEO of Velcura Therapeutics Inc. Named the 2008 Grant Thornton Leader and Innovator of the Year 3EUSA Pharma Completes Acquisition Of Cytogen Corporation 2EUSA Pharma Completes Acquisition Of Cytogen Corporation 3Takeda Successfully Completes Tender Offer for Millennium Pharmaceuticals, Inc. and Announces Subsequent Offering Period 2Takeda Successfully Completes Tender Offer for Millennium Pharmaceuticals, Inc. and Announces Subsequent Offering Period 3Takeda Successfully Completes Tender Offer for Millennium Pharmaceuticals, Inc. and Announces Subsequent Offering Period 4Takeda Successfully Completes Tender Offer for Millennium Pharmaceuticals, Inc. and Announces Subsequent Offering Period 5
(Date:5/21/2012)... premature babies enter the world with a mountain of ... any life-threatening issues, they face ongoing, and typically unpleasant, ... chronic health issues throughout their lives. , To ... how to suck and feed Florida State University ... (PAL) device to hospitals around the world. , ...
(Date:5/21/2012)... - The brown tissue that signals blossom end rot ... and home gardeners, but a Purdue University researcher has ... the disease sitting on a shelf for 20 years. ... developed a transgenic tomato with a thicker juice that ... tomatoes. He said large commercial producers were interested but ...
(Date:5/21/2012)... the spread of harmful mercury in plants and animals, ... University and The National Aquarium has compared levels of ... the wild. The captive animals were fed a controlled ... that may carry more of the toxic metal., The ... animals, particularly compared to wild dolphins tested off the ...
Breaking Biology News(10 mins):New musical pacifier helps premature babies get healthy 2New musical pacifier helps premature babies get healthy 3Blossom end rot plummets in Purdue-developed transgenic tomato 2Mercury in dolphins: Study compares toxin levels in captive and wild sea mammals 2Mercury in dolphins: Study compares toxin levels in captive and wild sea mammals 3Gilson Inc Selects EDL Consulting 26apos 3Bs CloudCraze For Cross Channel Webstore Expansion in Europe 16358 1Gilson Inc Selects EDL Consulting 26apos 3Bs CloudCraze For Cross Channel Webstore Expansion in Europe 16358 2Gilson Inc Selects EDL Consulting 26apos 3Bs CloudCraze For Cross Channel Webstore Expansion in Europe 16358 3Pfizer Global Manufacturing Announces Plans to Reconfigure Its Global Plant Network 16355 1Pfizer Global Manufacturing Announces Plans to Reconfigure Its Global Plant Network 16355 2Pfizer Global Manufacturing Announces Plans to Reconfigure Its Global Plant Network 16355 3Pfizer Global Manufacturing Announces Plans to Reconfigure Its Global Plant Network 16355 4Pfizer Global Manufacturing Announces Plans to Reconfigure Its Global Plant Network 16355 5Pfizer Global Manufacturing Announces Plans to Reconfigure Its Global Plant Network 16355 6Pfizer Global Manufacturing Announces Plans to Reconfigure Its Global Plant Network 16355 7Redsense Medical Receives FDA Clearance for the Redsense Safety Device for Home Self use During Home Hemodialysis 16353 1Redsense Medical Receives FDA Clearance for the Redsense Safety Device for Home Self use During Home Hemodialysis 16353 2
... bisporus) has as much, and in some cases, more anti-oxidant ... is the foremost cultivated edible mushroom in the world with ... thought of as a poor relation to its more exotic ... But according to new research in SCIs Journal of the ...
... of surface-drifting plankton algae are able to significantly reduce the ... the global carbon dioxide cycle. This is one of the ... a close in Cape Town on February 4, and which ... Helmholtz Association. On February 5, an international team of scientists ...
... Rochet, a research scientist at IFREMER (The French Research ... the prestigious Pew Fellowship in Marine Conservation to determine ... to the delicately balanced marine ecosystem. She will use ... use of that technique, and to further improve its ...
Other Biology News:Antarctic expedition provides new insights into the role of the Southern Ocean for global climate 2Antarctic expedition provides new insights into the role of the Southern Ocean for global climate 3Antarctic expedition provides new insights into the role of the Southern Ocean for global climate 42008 Pew Fellowship in Marine Conservation awarded to Dr. Marie-Joëlle Rochet from IFREMER 22008 Pew Fellowship in Marine Conservation awarded to Dr. Marie-Joëlle Rochet from IFREMER 32008 Pew Fellowship in Marine Conservation awarded to Dr. Marie-Joëlle Rochet from IFREMER 4
... Thermo Labsystems' Wellwash AC is ... microplate washer available, and is ... for wash, waste and rinse ... and automatic rinsing and priming ...
... Rabbit polyclonal to MLF1 Interacting Protein/PBIP1 ... all tested applications). ... to amino acids 73-83 of Human ... Entrez Gene ID: 359815 ...
... save space and organize gloves, safety ... They are the perfect benchtop storage ... labs, processing and manufacturing. Clear static-dissipative ... particles they attract. Many other sizes ...
... These handy dispensers save space ... wipers, hats, and other garb. ... storage bins for small parts ... manufacturing. Clear acrylic. Many other ...
Biology Products: